Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Arecor Therapeutics PLC (GB:AREC)
LSE:AREC
RESEARCH TOOLSreports
Holding GB:AREC?
Track your performance easily
AREC Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range68.25p - 199.00p
Previous Close68.5p
Volume20.77K
Average Volume (3M)7.08K
Market Cap
£25.86M
Enterprise Value13.35M
Total Cash (Recent Filing)£12.81M
Total Debt (Recent Filing)£288.00K
Price to Earnings (P/E)―
Beta-0.28
Next Earnings
Sep 26, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding37,756,601
10 Day Avg. Volume10,214
30 Day Avg. Volume7,082
Standard Deviation0.16
R-Squared0.00596
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)214.29
Price to Sales (P/S)6.28
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Arecor Therapeutics PLC News
PremiumCompany Announcements
Arecor Therapeutics Announces Upcoming Interim Results
PremiumCompany Announcements
Arecor’s Insulin AT278 Shows Promise for Diabetes Care
PremiumCompany Announcements
Arecor’s Breakthrough Insulin AT278 Shows Promise
PremiumCompany Announcements
Arecor Therapeutics Shareholder Structure Shifts
PremiumCompany Announcements
Arecor Therapeutics Stakeholder Shift Notified
PremiumCompany Announcements
Arecor Therapeutics Reports Major Shareholding Change
PremiumCompany Announcements
Arecor Therapeutics Seals Shareholder Approval for Fundraising
PremiumCompany Announcements
Arecor Therapeutics Schedules Key Fundraising MeetingOptions Prices
Currently, No data available
---
Ownership Overview
6.38% Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
93.62% Public Companies and
Individual Investors
AREC FAQ
What was Arecor Therapeutics PLC’s price range in the past 12 months?
Arecor Therapeutics PLC lowest share price was 68.25p and its highest was 199.00p in the past 12 months.
What is Arecor Therapeutics PLC’s market cap?
Currently, no data Available
When is Arecor Therapeutics PLC’s upcoming earnings report date?
Arecor Therapeutics PLC’s upcoming earnings report date is Sep 26, 2024 which is in 5 days.
How were Arecor Therapeutics PLC’s earnings last quarter?
Arecor Therapeutics PLC released its earnings results on May 16, 2024. The company reported -0.131p earnings per share for the quarter, missing the consensus estimate of N/A by -0.131p.
Is Arecor Therapeutics PLC overvalued?
According to Wall Street analysts Arecor Therapeutics PLC’s price is currently Overvalued.
Does Arecor Therapeutics PLC pay dividends?
Arecor Therapeutics PLC does not currently pay dividends.
What is Arecor Therapeutics PLC’s EPS estimate?
Arecor Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arecor Therapeutics PLC have?
Arecor Therapeutics PLC has 37,756,600 shares outstanding.
What happened to Arecor Therapeutics PLC’s price movement after its last earnings report?
Arecor Therapeutics PLC reported an EPS of -0.131p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.029%.
Which hedge fund is a major shareholder of Arecor Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:AREC
---
Arecor Therapeutics PLC Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth £85.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.41%
12-Months-Change
Fundamentals
Return on Equity
-63.41%
Trailing 12-Months
Asset Growth
-29.35%
Trailing 12-Months
Company Description
Arecor Therapeutics PLC
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Arestat, it is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies.
---
Technical Analysis
HUTCHMED (China) Limited
―
N4 Pharma
―
4basebio UK Societas
―
Achilles Therapeutics
―
---